title: Amelioration of microvascular myocardial ischemia by gene transfer of vascular endothelial growth factor in rabbits.
abstract: OBJECTIVE
  Restoration of coronary blood flow by angiogenesis may offer a new approach to intractable ischemic heart disease. In the present study, we investigated the angiogenic effects of gene transfer of vascular endothelial growth factor 165 on microvascular myocardial ischemia.
  
  
  METHODS
  A rabbit model of microvascular myocardial ischemia was created by plugging coronary microvessels with microspheres (15 microm in diameter, 2.8 x 10(5)/kg, n = 29). Gene transfer was performed by semi-selective intracoronary injection of recombinant adenovirus expressing vascular endothelial growth factor 165 forty minutes after microsphere injection (n = 9).
  
  
  RESULTS
  Microsphere injection reduced myocardial perfusion (78% +/- 9% of baseline tissue flow) and diminished myocardial contraction (61% +/- 12% of the baseline ejection fraction) and cardiac performance (elevated left ventricular end-diastolic pressure and decreased systemic flow) in the acute phase. At 17 +/- 3 days, gene transfer of vascular endothelial growth factor 165 had had the following effects: (1) promoted coronary angiogenesis as evidenced by myocardial flow above the baseline (121% +/- 24%), (2) increased vascular density revealed by synchrotron radiation microangiography and histologic analysis, (3) ameliorated the degree of myocardial ischemia as evidenced by myocardial lactate content and the extent of histologic necrosis, and (4) restored heart function as evidenced by increased ejection fraction (95% +/- 10%), reduced left ventricular end-diastolic pressure, and restored body weight.
  
  
  CONCLUSIONS
  In vivo vascular endothelial growth factor 165 gene transfer promoted angiogenesis and was an effective approach to treating microvascular myocardial ischemia.
authors.affiliation: Department of Physiology, the Reserch Center for Genetic Engineering and Cell Transplantation, Tokai University School of Medicine, Isehara, Japan.
authors.forename: E
authors.initials: E
authors.lastname: Tanaka
authors.forename: N
authors.initials: N
authors.lastname: Hattan
authors.forename: K
authors.initials: K
authors.lastname: Ando
authors.forename: H
authors.initials: H
authors.lastname: Ueno
authors.forename: Y
authors.initials: Y
authors.lastname: Sugio
authors.forename: M U
authors.initials: MU
authors.lastname: Mohammed
authors.forename: S A
authors.initials: SA
authors.lastname: Voltchikhina
authors.forename: H
authors.initials: H
authors.lastname: Mori
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000704:Analysis of Variance; D000818:Animals; D003331:Coronary Vessels / Q000187:drug effects; D004195:Disease Models, Animal; D016228:Endothelial Growth Factors / Q000235:genetics / Q000627:therapeutic use*; D015316:Genetic Therapy; D008222:Lymphokines / Q000235:genetics / Q000627:therapeutic use*; D008863:Microspheres; D017202:Myocardial Ischemia / Q000628:therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D011817:Rabbits; D012039:Regional Blood Flow / Q000187:drug effects; D018709:Statistics, Nonparametric; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors